29.11.2025 20:26
π 0
π 0
π¬ 0
π 0
IgA-dominant Anti-GBM & isolated pulmonary disease
β’ Overlap with other GN forms
β’ Special situations: pregnancy & pediatrics
β’ Imlifidase updates
β’ Personalized approaches & future directions
β’ Mechanisms & integrated biology
β’ Diagnostic pearls, classic and atypical presentations
β’ Transplant recurrence
β’ Standard vs emerging management strategies
β’ Dialysis-dependent cases & futility criteria
β’ Relapse, refractory disease & double-positive cases
π₯Hello dear colleagues,
Iβve just finished my new Anti-GBM presentation
It covers every single new insight you need to know:
I truly hope you find this deep-dive clear, practical, and useful.
*Link:* youtu.be/rIqiNhF0scY?...
When training nephrology residents, cultivating the skill to frame insightful questions and construct well-reasoned answers is far more valuable than offering quick, simple replies.
My new friend! π€π
Nephrology wasnβt a planned choice for me, but with time I genuinely fell in love with it.
π₯This new lecture. The first focuses on clinical reasoning in nephrology through an atypical case of HTN emergencie in a young boy, recently published AJKD case, and the second covers practical tips and tricks for approaching the hypokalemia-hypertension algorithm.
*Link:* youtu.be/ADV0zbXnosQ?...
π₯Passion and medical learning
youtu.be/A0fSbAbUAk4?...
π₯My presentation on CRRT practice:
youtu.be/7mpcvHkAjKQ?...
The Mayo Imaging Classification of ADPKD description (left panel) and imaging examples (right panel) with examples (right panel) of (a, b) subclass 1A and 1E, (c-f) subclass 2A, and (g, h) subclass 2B. Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; TKV, total kidney volume. Reproduced with permission of the copyright holder (Kidney Disease: Improving Global Outcomes) from Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int. 2025;107(suppl 2S):S1-S239. doi:10.1016/j.kint.2024.07.009
Core Curriculum by Craig E. Gordon et al:
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)
Thirst, sodium, and the hospitalized child: rethinking hypernatremia
(Editorial Commentary )
I donβt get it β BlueSky feels almost identical to X. The only real difference for me is that I have more control over my feed and can focus on medical content only. My question is: why do so many people whoβve moved to BlueSky still post the same content on X? It seems like double the effort.
Highlights from my talk yesterday on Alport syndrome spectrum of disorders. (since no one posted it, I'll have to do it myself)
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk π§΅
π₯Decoding acid base disturbances!π§©π§©
youtu.be/yNHfuLRJh_g?...
π§π’πππ¬: ISN KHPWG webinar: "Physical Examination of Arteriovenous Access: from inspection to clinical decision."
π£οΈ Polyana Bezerraβ―MendonΓ§a, Jim Escobar Torres
π€ Clemente Sousa
ποΈ November 4
π 5 pm CET
π Free registration: http://lite.spr.ly/6...
π§The Nephrologistβs Perspective in Evaluation and Management of Localized Renal Masses
Gain key insights into nephrologyβs role in diagnosing and managing localized renal masses.
π Listen now: bit.ly/3DamjQ9
Foamy podocytes and myelinosomes in a case of Fabry's disease. This patient had positive genetic testing.
#nephsky #pathsky #kidneypath #renal
π₯HIV associated TMA!
Join us tomorrow, Nov. 4 @ 3pm ET, for an expert-led KDIGO-@medliveofficial.bsky.social webinar on the KDIGO #IgAN Guideline.
Register: bit.ly/4oxpVO3
Learn about updated treatment strategies, emerging therapies, and key safety considerations to support better care for people living with IgAN.
Nodular, amorphous, acellular mesangial deposits that are pale, eosinophilic, and PAS weakly positive.
For Congo red stain.
10 tips on IS in primary MNπ―
youtu.be/uFmheG-VM_w?...
π₯What nephrologist should know about renal pathology!
youtu.be/koYYMcW95Qs?...
My presentation about EULAR 2025 - LN update!
youtu.be/lNrKWE5PGHI?...
π₯Dilutional acidosis!π°
How I consult on cardiorenal syndrome:
β’ Bump furosemide from 20 to 60 mg bid IV
β’ Consider rapid resumption of sacubitril/valsartan and empagliflozin. Let's not treat these life saving medications as nephrotoxins.
Interesting case from the Skeleton Key Group which just keeps pumping out the #FOAMed
www.renalfellow.org/2025/09/28/s...
π§©PLEX!
π§©Causes of CK elevation!
π―Myopathy
π―Vitamin D deficiency
π―Carnitine deficiency
π―Reduced renal clearance
π₯H2 receptor antagonists are renally excreted but generally prescribed safely, with no dose modification.
Cimetidine is best avoided: it interacts with cytochrome P450 enzymes, causing drug interactions, and falsely elevates SCr through the inhibition of active urinary creatinine secretion.